Skip to content
  • Hepatitis C drugs re-energize global fight over patents

    Nature News - 03/01/2017

    Public-health experts say that expanding access to the drugs would have immediate benefits. Roughly 177.5 million adults worldwide are infected with the hepatitis C virus, which can cause liver cancer and cirrhosis if left untreated — but the latest antiviral medications have revolutionized care. The first to reach the market was sofosbuvir, sold under the name Sovaldi by Gilead Sciences of Foster City, California; clinical trials of the drug in combination with other medications have shown a cure rate of 95% or more. “If these medicines were made widely available, you could make a plan to eliminate this disease,” says Brook Baker, a law specialist at Northeastern University in Boston, Massachusetts.

  • Cookies on Northeastern sites

    This website uses cookies and similar technologies to understand your use of our website and give you a better experience. By continuing to use the site or closing this banner without changing your cookie settings, you agree to our use of cookies and other technologies. To find out more about our use of cookies and how to change your settings, please go to our Privacy Statement.